A phase 1b study of SENS-300 to protect the inner ear from the toxicity of certain drugs and thus prevent balance disorders and loss of hearing

Trial Profile

A phase 1b study of SENS-300 to protect the inner ear from the toxicity of certain drugs and thus prevent balance disorders and loss of hearing

Planning
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs SENS 300 (Primary)
  • Indications Ear disorders; Hearing loss
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Aug 2015 New trial record
    • 30 Mar 2015 According to Sensorion media release, company is planning to initiate this trial in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top